Edgewise Therapeutics (EWTX) Accounts Payables (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Accounts Payables data on file, last reported at $7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 17.02% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 17.02% YoY), and the FY2025 full-year result was $6.0 million, up 7.65% from the prior year.
• Accounts Payables climbed to $7.3 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.8 million in Q1 2025 to a low of $2.8 million in Q2 2022.
• A 5-year average of $5.7 million and a median of $5.6 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 229.43% in 2022 and plunged 34.07% in 2023, its largest moves.
• Tracing EWTX's Accounts Payables over 5 years: stood at $6.1 million in 2022, then slumped by 34.07% to $4.0 million in 2023, then soared by 38.61% to $5.6 million in 2024, then gained by 7.65% to $6.0 million in 2025, then climbed by 21.43% to $7.3 million in 2026.
• Business Quant data shows EWTX's Accounts Payables at $7.3 million in Q1 2026, $6.0 million in Q4 2025, and $6.2 million in Q3 2025.